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ABSTRACT
Introduction The evidence currently available from 
enhanced recovery after surgery (ERAS) programmes 
concerns their benefits in the immediate postoperative 
period, but there is still very little evidence as to whether 
their correct implementation benefits patients in the long 
term. The working hypothesis here is that, due to the 
lower response to surgical aggression and lower rates of 
postoperative complications, ERAS protocols can reduce 
colorectal cancer- related mortality. The main objective of 
this study is to analyse the impact of an ERAS programme 
for colorectal cancer on 5- year survival. As secondary 
objectives, we propose to analyse the weight of each of 
the predefined items in the oncological results as well as 
the quality of life.
Methods and analysis A multicentre prospective 
cohort study was conducted in patients older than 18 
years of age who are scheduled to undergo surgery for 
colorectal cancer. The study involved 12 hospitals with 
an implemented enhanced recovery protocol according 
to the guidelines published by the Spanish National 
Health Service. The intervention group includes patients 
with a minimum implementation level of 70%, and the 
control group includes those who fail to reach this level. 
Compliance will be studied using 18 key performance 
indicators, and the results will be analysed using cancer 
survival indicators, including overall survival, cancer- 
specific survival and relapse- free survival. The time to 
recurrence, perioperative morbidity and mortality, hospital 
stay and quality of life will also be studied, the latter using 
the validated EuroQol Five questionnaire. The propensity 
index method will be used to create comparable treatment 
and control groups, and a multivariate regression will be 
used to study each variable. The Kaplan- Meier estimator 
will be used to estimate survival and the log- rank test to 
make comparisons. A p value of less than 0.05 (two- tailed) 
will be considered to be significant.
Strengths and limitations of this study
 ► This is the first multicentre prospective study intend-
ing to analyse whether the correct implementation 
of an intensified recovery programme (enhanced re-
covery after surgery) in patients undergoing colorec-
tal surgery for cancer is related to better long- term 
oncological outcomes.
 ► The study will also try to analyse the influence 
(weight) of each perioperative protocol items on the 
oncological outcome.
 ► The research project will be monitored closely by a 
certified external auditor to ensure that study activi-
ties are carried out in accordance with the protocol, 
good clinical practice and applicable regulatory re-
quirements. Data quality will also be audited.
 ► The study is designed as a prospective, non- 
randomised study.
 ► The study could have difficulty in recruiting patients 
due to potential structural or multidisciplinary team 
problems.









pen: first published as 10.1136/bm





2 Ramirez- Rodriguez J- M, et al. BMJ Open 2020;10:e040316. doi:10.1136/bmjopen-2020-040316
Open access 
Ethics and dissemination Ethical approval for this study was obtained 
from the Aragon Ethical Committee (C.P.-C.I. PI20/086) on 4 March 
2020. The findings of this study will be submitted to peer- reviewed 
journals (BMJ Open, JAMA Surgery, Annals of Surgery, British Journal of 
Surgery). Abstracts will be submitted to relevant national and international 
meetings.
Trial registration number NCT04305314.
INTRODUCTION
Colorectal cancer is the third most frequent neoplasm 
in men worldwide (746 000 cases, approximately 10.0% 
of the total) and the second most common in women 
(614 000 cases, 9.2%). Surgery remains a cornerstone 
of treatment for this type of malignant tumour.1 In this 
regard, surgical treatment with curative intent is indi-
cated in about 80% of cases, with a 5- year overall survival 
rate of approximately 65%.2 It is well known that any 
surgical procedure can lead to adverse events, with 
surgery- related complications depending on the degree 
of aggression (stress), the basal state of the patient and 
the disease itself. Postoperative complications after major 
surgery have been shown to increase both the length of 
hospital stay and cost while decreasing long- term survival 
as an independent factor.3 4 Colorectal surgery is consid-
ered a high risk and is associated with a high rate of 
morbidity and mortality in the immediate postoperative 
period. Despite ‘curative intent’ surgery, 5- year survival in 
colorectal cancer has remained stable at around 60% in 
recent decades. Metastatic disease is the most important 
cause of cancer- related death in patients after surgery.5 
Although there has been much speculation about 
the occurrence of metastasis, surgical manipulation is 
known to lead to significant systemic release of tumour 
cells.6 7 Whether these cells lead to metastasis depends 
largely on the balance between the aggressiveness of 
the tumour cells and the resistance of the patient. As we 
have discussed previously, surgery ‘per se’ induces a stress 
response that can decrease host defences and promote 
tumour growth. Furthermore, innate immunity and, 
especially, natural killer (NK) cells are known to play an 
important role in the elimination of circulating tumour 
cells.8 Several studies have shown decreased postopera-
tive NK cell activity and an inverse correlation of NK cell 
activity with tumour stage and metastatic growth.9
Until a few years ago, the perioperative treatment of 
patients undergoing elective abdominal surgery consisted 
of a series of habits acquired by practice rather than scien-
tifically proven facts. In the early 2000s, ERAS (enhanced 
recovery after surgery) protocols based mainly on 
Kehlet’s work began to be introduced in some centres. 
These programmes rest on three fundamental pillars: the 
application of a package of perioperative measures and 
strategies; interdisciplinarity, understood to be the joint 
and structured participation of the various health profes-
sionals involved; and active participation of the patient 
throughout the process. The various ERAS protocol 
recommendations include anaesthesia/analgesia, goal- 
directed fluid therapy, prevention of nausea and ileus, 
thromboembolic prophylaxis, minimally invasive tech-
niques, temperature control, early nutrition and early 
mobilisation.
A number of randomised studies and meta- analyses 
carried out in the first decade of this century served 
to demonstrate that these protocols both shorten the 
hospital stay and decrease complications, outcomes that 
have been linked to the amelioration of perioperative care 
and the reduction in the response to surgical stress.10 11
As mentioned previously, the response to surgical 
stress results in hormonal and metabolic changes that 
produce immune and endocrine responses propor-
tionally to the extent of the surgical tissue injury. Local 
changes affect the inflammatory reaction throughout the 
body, leading to widespread effects on organ function 
and the development of complications. In this regard, 
numerous studies have pointed out that the main reason 
for the effectiveness of ERAS programmes is based on the 
ability of each element to reduce the stress response to 
injuries and maintain homeostasis.12 Hence, prevention 
of the stress response is the key mechanism underlying 
perioperative ERAS programmes.13 Moreover, since a 
lower surgical aggression has evident advantages in the 
immunometabolic response of the patient with cancer, it 
could be deduced that, in these cases, long- term survival 
is favoured.
A fundamental factor in the success of multimodal 
treatment is the degree of completion of the programme. 
Gustafsson et al14 have shown the existence of a dose- 
response relationship and have highlighted the need 
to fulfil more than 70% of the items. In this sense, it is 
suggested that the more items of the programme are 
implemented, the better the patient’s postoperative 
course.15
In a recent study from our group,16 we were able to 
verify that despite having undergone training and having 
established an ERAS protocol in colorectal surgery, it 
was not fully implemented in daily clinical practice, with 
certain elements of the protocol having very low compli-
ance, even in specialised centres. In this same study, which 
involved 2084 patients from 80 centres in our country, 
we found that an increase in compliance with evidence- 
based recommendations that constitute the PRI is associ-
ated with a decrease in postoperative complications.
As noted above, the evidence currently available 
concerns the benefits of such programmes in the imme-
diate postoperative period, and there is still very little 
evidence as to whether the proper implementation of 
an ERAS protocol benefits patients in the long term. In 
this respect, Gustafsson et al17 analysed 5- year survival in 
a retrospective study and found that patients who were 
more compliant with an ERAS programme (≥70% of 
the protocol) exhibited a reduced risk of cancer- specific 
death at 5 years (HR: 0.58; 95% CI: 0.39 to 0.88). Other 
studies18–20 have addressed the relationship between 
ERAS programmes and overall and disease- free survival 
after colorectal surgery for cancer, although none have 
provided sufficient evidence to draw any firm conclusions.
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This study has been designed to support the working 
hypothesis that the correct implementation of an inten-
sified recovery programme in patients undergoing 
colorectal surgery for cancer is related to better long- 
term oncological outcomes.
The primary objective is the analysis of survival at 5 years, 
overall survival, disease- related survival and disease- free 
survival.
The secondary objectives are to (1) evaluate the rela-
tionship between adherence to the protocol and 5- year 
survival, (2) analyse the importance of each item on 
survival and (3) evaluate the quality of life.
The data generated from this prospective, multicentre, 
observational cohort study will help to verify or better 
understand the suspected benefits of ERAS protocols 
regarding long- term survival in patients who have under-




A prospective, multicentre, observational cohort study in 
patients who meet the inclusion criteria.
Setting
This study will be conducted in 12 Spanish general hospi-
tals, which were selected on the basis of having established 
an enhanced recovery protocol that complies with the 
recommendations of the Aragon Health Sciences Institute 
(IACS) and Spanish National Health Service (https:// 
portal. guiasalud. es/ wp- content/ uploads/ 2019/ 10/ 
viaclinica- rica_ english. pdf). All hospitals selected have 
received prior standardised training according to the 
national plan for the implementation of intensified 
recovery in surgery (IMPRICA), also promoted by the 
IACS.
Inclusion criteria
All adult patients (aged >18 years) with a diagnosis of 
malignant colorectal cancer who are scheduled for 
radical surgery. Informed consent will be obtained from 
all subjects who will participate in the study voluntarily.
Exclusion criteria
Patient refusal, patients undergoing emergency surgery, 
patients under 18 years of age, patients diagnosed with 
stage IV cancer and existence of other concomitant 
surgical processes.
Comparison groups
As mentioned previously, the literature considers adequate 
implementation of a protocol to be compliance of more 
than 70%. As such, two groups will be formed: one with 
more than 70% of the recorded items performed and 
the other with those that do not reach this percentage 
(table 1).
Outcome measures
The primary outcome measures are overall survival 
(patients alive from surgery to the last control), disease- 
free survival (number of patients alive and without cancer 
recurrence from the intervention period until the end of 
follow- up) and disease recurrence (detected by CT or 
Flexible Colonoscopy (FCC), from the day of the inter-
vention until the end of follow- up), which will also be 
studied.
Secondary outcome measures include compliance with 
individual protocol items and quality of life according to 
the EuroQol Five questionnaire.
Follow-up
The study is planned to start in September 2020, and for 
the survival study only patients with a minimum follow- up 
of 3 years will be considered. However, patients will still be 
recruited until the end of the 5- year period (September 
2025) to allow study of the secondary objectives.
The follow- up plan is as follows: tumour markers (used 
to monitor colorectal neoplasia)—carcinoembryonic 
antigen determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 
48 and 60 months and cancer antigen 19.9 determined 
at 3, 6,9,12, 15, 18, 21, 24, 30, 36, 42, 48 and 60 months; 
abdominal ultrasound performed at 3, 9, 15, 21, 36, 48 
and 60 months; CT performed at 6, 12, 24, 36, 48 and 60 
months; and complete colonoscopy performed at 2 and 
5 years after intervention.
Data collection and data management
Data will be collected using an online data collection 
form via a secure, password- protected platform with 
predefined data fields at each centre. The variables to 
be collected are displayed in table 2. For the purpose 
of the study, we will record the following: complications 
at 60- day follow- up (surgical complications, infectious 
complications, cardiovascular complications), each 
rated as mild, moderate or severe and also according to 
the Clavien- Dindo classification; perioperative mortality 
(the number and percentage of deaths within 60 days of 
surgery); hospital stay, defined as the duration from the 
date of the end of surgery to the date of discharge from 
the hospital (in days); overall survival (the number and 
percentage of deaths that occur from the intervention to 
the end of follow- up); disease- free survival (the number 
of patients alive and with no cancer recurrence from the 
intervention period to the end of follow- up); and recur-
rence of the disease (detected by CT or FCC), from the 
day of the intervention until the end of follow- up.
The data collection platform Castor EDC (https://www. 
castoredc. com) will be used. This platform complies with 
all applicable laws and regulations. All identifiable data 
collected, processed and stored for the purposes of the 
project will be kept confidential at all times and comply 
with Good Clinical Practice guidelines for Research and 
the General Data Protection Regulation (Regulation 
(EU) 2016/679).
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The research project will be monitored closely by a 
certified external auditor to ensure that study activities 
are carried out in accordance with the protocol, good 
clinical practice and applicable regulatory requirements. 
Local study documents can be selected for a local audit at 
participating hospitals. Data quality will also be audited.
Statistical analysis
According to the Postoperative Outcomes Within 
Enhanced Recovery After Surgery Protocol in Colorectal 
Surgery study that includes data from 82 Spanish hospi-
tals,16 only 60% of centres with an ERAS protocol achieve 
more than 70% compliance. As such, we consider a 
scenario of seven high- compliance (HC) and five low- 
compliance (LC) centres among the 12 hospitals that will 
collaborate with this research project. Estimating a differ-
ence in overall survival of around 10% (65% LC vs 75% 
HC), with a power of 80%, a 95% CI and 5% of potential 
losses, the required sample size is about 732 patients (366 
in each group).
Given that the main objective (survival) may be subject 
to aspects inherent to each centre, irrespective of the 
intervention, it will be necessary to create comparable 
groups using the propensity score method (propensity 
score matching). A descriptive analysis of the data will 
be carried out. Qualitative variables will be represented 
by a frequency distribution of the percentages for each 
category, and quantitative variables will be explored using 
the Kolmogorov- Smirnov conformity test. The association 
Table 1 EEAS compliance definitions
Individual ERAS items included Definitions of ERAS compliance for individual items included
1 Presurgical education Verbal and written ERAS education received at a dedicated preadmission visit
2 Presurgical optimisation Patients stopped smoking 4 weeks before surgery, and alcoholics ceased all 
alcohol consumption 4 weeks before surgery
3 Preoperative fasting Preoperative fasting limited to 2 hours for clear liquids (water, coffee, juice without 
pulp) and 6 hours for solids
4 Patient blood management Set of measures applied to optimise preoperative haemoglobin, avoid bleeding 
and avoid transfusion
5 Preoperative carbohydrate drink 
preload
Preoperative carbohydrate drink defined as at least 50 g of carbohydrate in at 
least 400 mL of fluid, given in the form of a dedicated preoperative beverage with 
a proven safety profile up until 2 hours before anaesthesia
6 Avoidance of long- acting sedative 
premedication
No long- acting sedative premedication given (eg, opioids, sedative antihistamines 
and neuroleptics)
7 Thromboprophylaxis Thromboprophylaxis (low- molecular- weight heparin and compression stockings) 
given
8 Antibiotic prophylaxis Antibiotic prophylaxis given before skin incision
9 Regional anaesthesia Anaesthetic procedure that allows rapid awakening, adequate analgesia 
and patient recovery. This item is considered positive provided that any 
major anaesthetic technique (spinal anaesthesia or general anaesthesia) is 
accompanied by local or locoregional anaesthesia techniques, or continuous 
epidural anaesthesia
10 PONV prophylaxis PONV prophylaxis given
11 Active prevention of unintentional 
hypothermia
Use of fluid heaters and/or thermal blanket for all patients during the surgical 
procedure
12 Goal- directed fluid therapy Intravenous fluid administration guided by haemodynamic goals based on the 
cardiac output or derived monitoring by any validated cardiac output monitoring
13 Laparoscopy or transverse incisions Laparoscopy is recommended, although this item will be considered positive in 
those cases in which minimal incisions are used despite an open approach,
14 Avoid drains This item will be considered positive when no drains are left after closure
15 Postoperative analgesia A multimodal analgesic management that includes at least two drugs to avoid or 
reduce the administration of morphics
16 Postoperative glycaemic control Patients receive glycaemic control in the first 24 hours, for target glycaemia 
<180 g/dL
17 Early mobilisation Defined as the patient moved at least to an armchair in the first 12 postoperative 
hours
18 Early feeding Defined as the patient tolerates oral feeding in the first 6 postoperative hours
ERAS, enhanced recovery after surgery; PONV, postoperative nausea and vomiting.
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between factors will be investigated using hypothesis 
contrast tests, with a comparison of proportions when 
both variables are qualitative (χ2, Fisher’s exact test), a 
comparison of mean when one of them is quantitative 
(Student’s t- test, analysis of variance (ANOVA), and the 
Mann- Whitney U test or the Kruskall- Wallis test if they do 
not follow a normal distribution) and a bivariate correla-
tion (Pearson correlation coefficient) when both are 
quantitative or the Spearman correlation if the conditions 
for application of the former are not met. For compari-
sons in related samples when one of them is quantitative, 
Student’s t- test and/or ANOVA will be used (Wilcoxon 
or Friedman’s test if they do not follow a normal distribu-
tion). The analysis will be completed using multivariate 
regression models. A survival analysis will be performed 
using the Kaplan- Meier method, and the log- rank test will 
be used for survival comparisons between groups. Effects 
will be considered to be significant with a p value of less 
than 0.05.
Patient involvement
The study is supported by a patient advisory group which 
helped us with the patient’s information material. This 
patient advisory group will meet on a regular basis for 
the duration of the study. At the end of the study, the 
patient advisory group will comment on the findings and 
contribute to the dissemination plan.
Limitations of the study
The limitations are those inherent to a prospective, 
non- randomised study, including difficulty in recruiting 
patients due to potential structural or multidisciplinary 
team problems and inappropriate number of patients in 
any of the arms due to a very high or very low level of 
compliance.
ETHICS AND DISSEMINATION
Ethical approval for this study was obtained from the 
Comité de Ética de la Investigación de la Comunidad 
Autónoma de Aragón (C.P.-C.I. PI20/086; on 4 March 
2020). Local ethical approval is required at each partici-
pating centre. Although this study has no impact on clin-
ical practice, informed consent will be requested from all 
participants. Patient data will be treated in accordance 
with the European General Data Protection Regulation 
2016/679. The findings of this study are being submitted 
to peer- reviewed journals (BMJ Open, JAMA Surgery, 
Annals of Surgery, British Journal of Surgery). Abstracts 
will be submitted to relevant national and international 
meetings.
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